Biomerica Inc (BMRA) 2.75 $BMRA
Biomerica to Present at 18th Annual Rodman & Renshaw Global Investment Conference
Marketwired - Tue Sep 06, 6:47AM CDT
IRVINE, CA--(Marketwired - September 06, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today announced that Zackary Irani, Chief Executive Officer, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11-13 in New York, New York, at the Lotte New York Palace Hotel.
BMRA: 2.75 (+0.01)
Biomerica Announces Year End Results
Marketwire Canada - Tue Aug 30, 8:29AM CDT
IRVINE, CA--(Marketwired - August 30, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today reported net sales for the fiscal year 2016 were $5,139,816 versus net sales of $4,962,373 in fiscal 2015. Net loss before income taxes was $795,987 for the fiscal year 2016 compared to $646,434 for fiscal 2015. Net loss was $1,499,787 for fiscal 2016 compared to net loss of $331,410 for fiscal 2015 primarily due to the recording of a non-cash income tax expense for the recognition of a valuation allowance of $703,000 against the Company's deferred tax asset compared to a non-cash tax benefit of $315,024 in fiscal 2015. Research and Development spending was $780,333 for fiscal year 2016 compared to $733,640 the previous year, an increase of $46,693. The company ended the year with $1,888,925 in cash and cash equivalents, working capital of $4,329,041 and less than $507,000 in total liabilities. The common stock of Biomerica (BMRA) started trading on NASDAQ on August 26, 2016.
BMRA: 2.75 (+0.01)
Biomerica Approved for Listing on the Nasdaq Capital Market
Marketwire Canada - Wed Aug 24, 7:19AM CDT
Company to Begin Trading on Nasdaq on August 26, 2016: Shares Will Trade as BMRA
BMRA: 2.75 (+0.01)
Biomerica Updates Shareholders on Progress of Commercialization of Its New IBS Product
Marketwire Canada - Wed Aug 10, 8:25AM CDT
IRVINE, CA--(Marketwired - August 10, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that has issued an update on the progress of commercialization of its new IBS diagnostic guided therapy product. The update was filed as a form 8-k filing as a letter to shareholders and is also available on the Biomerica website under the "Our Company" tab under Investor Relations. A summary of the update is below.
BMRA: 2.75 (+0.01)
Biomerica Signs Exclusive License Agreement for Korean Market With Total Value of up to $8.5 Million; Licensee Makes Equity Investment of $1m in Biomerica at $3 per Share
Marketwired - Thu May 26, 8:09AM CDT
IRVINE, CA--(Marketwired - May 26, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that it has entered into an exclusive license agreement with Celtis Pharm Co. Ltd of South Korea granting Celtis an exclusive license to market and sell Biomerica's new InFoods® IBS (Irritable Bowel Syndrome) products in Korea. The InFoods® IBS products identify patient-specific trigger foods that exacerbate IBS symptoms. Under the terms of the agreement, Celtis shall pay up to $1.25 million in exclusivity fees to Biomerica based on certain milestones including receipt of US FDA clearance. In addition to the exclusivity fees, a royalty fee shall be paid to Biomerica based on a percentage (in the mid-teens) of net sales of the products in Korea. The minimum royalty payments required to retain the exclusivity in Korea for the term of the agreement are $7.25 million over five years.
BMRA: 2.75 (+0.01)
Biomerica Announces Third Quarter Financial Results, Sales up 10% for Nine Months
Marketwired - Fri Apr 15, 6:47AM CDT
Biomerica, Inc. (OTCQB: BMRA) today reported net sales of $3,813,683 for the nine months ending February 29, 2016, compared to $3,467,450 for the same period in the previous year. Sales for the three months ending February 29, 2016 were $1,361,608 compared to $1,299,400 for the same period last year.
BMRA: 2.75 (+0.01)
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 41.58 (-0.10), MYGN: 20.76 (-0.11), VIVO: 19.15 (-0.14), A: 45.71 (+0.76), DHR: 76.72 (-0.09), ABAX: 51.48 (+0.73), DGX: 83.10 (-0.18), TRIB: 12.78 (-0.21), BMRA: 2.75 (+0.01), HOLX: 38.24 (+0.33)
World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 20.90 (+0.59), AFFX: 14.01 (+0.02), CPHD: 52.49 (-0.07), BMRA: 2.75 (+0.01)
Biomerica posts lower Q2 net loss of USD66,768
M2 - Mon Jan 18, 6:08AM CST
Biomedical company Biomerica (OTC BB:BMRA) stated on Friday that it recorded a net loss of USD66,768 (USD0.01 per share) for the three months ended 30 November 2015.
BMRA: 2.75 (+0.01)
Biomerica Announces Second Quarter Financial Results
Marketwired - Fri Jan 15, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $1,165,080 for the three months ended November 30, 2015, compared to $1,133,600 for the same period in the previous year. Net sales were $2,452,073 for the first six months of fiscal 2016 compared to $2,168,050 for the first six months in fiscal 2014, an increase of 13.1%.
BMRA: 2.75 (+0.01)
Biomerica Announces Executive Advisor Appointment for Medical Affairs and Research
Marketwired - Fri Jan 08, 6:11AM CST
Biomerica Inc. (OTCBB: BMRA) announced today the appointment of Charles A. Carter, PharmD, MBA, as a senior advisor with the main responsibilities of Executive Director of Medical Affairs and Research. He will work with the company's Scientific Advisory Board and management to develop and implement strategies to successfully guide products through developmental and regulatory FDA processes.
BMRA: 2.75 (+0.01)
OxySure (OXYS) Launches OxyTrac(TM) to Save Lives & Help Companies Stay Compliant
ACCESSWIRE - Thu Dec 10, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / December 10, 2015 / Suppose that you're at a sporting event and someone in the crowd suffers a heart attack and goes into cardiac arrest. A nearby fan responds quickly and calls for help, but stadium employees aren't quite sure where the nearest AED is located. Once a device is finally located, emergency responders attempt to utilize it, but the battery has died. The person ends up dying at the event and the sporting event is sued for their lack of an appropriate response.
SMED: 4.43 (unch), BMRA: 2.75 (+0.01)
Biomerica Reports First Quarter Results; Sales Up Over 24%
Marketwired - Fri Oct 16, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2015.
BMRA: 2.75 (+0.01)
Biomerica Working With FDA on Submission for Its IBS Product
Marketwired - Tue Sep 29, 6:47AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced today that following a meeting with FDA on September 17, 2015, Biomerica is moving forward with guidance from FDA to develop the optimal clinical and regulatory path to begin clinical studies for its new IBS (Irritable Bowel Syndrome) product. The product is intended to aid in identifying patient specific foods that may exacerbate IBS symptoms. The regulatory path Biomerica is pursuing is a De Novo 510(k) which, if accepted by FDA, would allow Biomerica to attain clearance of its product without filing a PMA (Premarket Approval Application). De Novo approval is generally faster and much less expensive than the PMA route.
BMRA: 2.75 (+0.01)
Biomerica to Present at 18th Annual Rodman & Renshaw Global Investment Conference
Marketwired - Tue Sep 06, 6:47AM CDT
IRVINE, CA--(Marketwired - September 06, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today announced that Zackary Irani, Chief Executive Officer, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11-13 in New York, New York, at the Lotte New York Palace Hotel.
BMRA: 2.75 (+0.01)
Biomerica Announces Year End Results
Marketwire Canada - Tue Aug 30, 8:29AM CDT
IRVINE, CA--(Marketwired - August 30, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today reported net sales for the fiscal year 2016 were $5,139,816 versus net sales of $4,962,373 in fiscal 2015. Net loss before income taxes was $795,987 for the fiscal year 2016 compared to $646,434 for fiscal 2015. Net loss was $1,499,787 for fiscal 2016 compared to net loss of $331,410 for fiscal 2015 primarily due to the recording of a non-cash income tax expense for the recognition of a valuation allowance of $703,000 against the Company's deferred tax asset compared to a non-cash tax benefit of $315,024 in fiscal 2015. Research and Development spending was $780,333 for fiscal year 2016 compared to $733,640 the previous year, an increase of $46,693. The company ended the year with $1,888,925 in cash and cash equivalents, working capital of $4,329,041 and less than $507,000 in total liabilities. The common stock of Biomerica (BMRA) started trading on NASDAQ on August 26, 2016.
BMRA: 2.75 (+0.01)
Biomerica Approved for Listing on the Nasdaq Capital Market
Marketwire Canada - Wed Aug 24, 7:19AM CDT
Company to Begin Trading on Nasdaq on August 26, 2016: Shares Will Trade as BMRA
BMRA: 2.75 (+0.01)
Biomerica Updates Shareholders on Progress of Commercialization of Its New IBS Product
Marketwire Canada - Wed Aug 10, 8:25AM CDT
IRVINE, CA--(Marketwired - August 10, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that has issued an update on the progress of commercialization of its new IBS diagnostic guided therapy product. The update was filed as a form 8-k filing as a letter to shareholders and is also available on the Biomerica website under the "Our Company" tab under Investor Relations. A summary of the update is below.
BMRA: 2.75 (+0.01)
Biomerica Signs Exclusive License Agreement for Korean Market With Total Value of up to $8.5 Million; Licensee Makes Equity Investment of $1m in Biomerica at $3 per Share
Marketwired - Thu May 26, 8:09AM CDT
IRVINE, CA--(Marketwired - May 26, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that it has entered into an exclusive license agreement with Celtis Pharm Co. Ltd of South Korea granting Celtis an exclusive license to market and sell Biomerica's new InFoods® IBS (Irritable Bowel Syndrome) products in Korea. The InFoods® IBS products identify patient-specific trigger foods that exacerbate IBS symptoms. Under the terms of the agreement, Celtis shall pay up to $1.25 million in exclusivity fees to Biomerica based on certain milestones including receipt of US FDA clearance. In addition to the exclusivity fees, a royalty fee shall be paid to Biomerica based on a percentage (in the mid-teens) of net sales of the products in Korea. The minimum royalty payments required to retain the exclusivity in Korea for the term of the agreement are $7.25 million over five years.
BMRA: 2.75 (+0.01)
Biomerica Announces Third Quarter Financial Results, Sales up 10% for Nine Months
Marketwired - Fri Apr 15, 6:47AM CDT
Biomerica, Inc. (OTCQB: BMRA) today reported net sales of $3,813,683 for the nine months ending February 29, 2016, compared to $3,467,450 for the same period in the previous year. Sales for the three months ending February 29, 2016 were $1,361,608 compared to $1,299,400 for the same period last year.
BMRA: 2.75 (+0.01)
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 41.58 (-0.10), MYGN: 20.76 (-0.11), VIVO: 19.15 (-0.14), A: 45.71 (+0.76), DHR: 76.72 (-0.09), ABAX: 51.48 (+0.73), DGX: 83.10 (-0.18), TRIB: 12.78 (-0.21), BMRA: 2.75 (+0.01), HOLX: 38.24 (+0.33)
World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 20.90 (+0.59), AFFX: 14.01 (+0.02), CPHD: 52.49 (-0.07), BMRA: 2.75 (+0.01)
Biomerica posts lower Q2 net loss of USD66,768
M2 - Mon Jan 18, 6:08AM CST
Biomedical company Biomerica (OTC BB:BMRA) stated on Friday that it recorded a net loss of USD66,768 (USD0.01 per share) for the three months ended 30 November 2015.
BMRA: 2.75 (+0.01)
Biomerica Announces Second Quarter Financial Results
Marketwired - Fri Jan 15, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $1,165,080 for the three months ended November 30, 2015, compared to $1,133,600 for the same period in the previous year. Net sales were $2,452,073 for the first six months of fiscal 2016 compared to $2,168,050 for the first six months in fiscal 2014, an increase of 13.1%.
BMRA: 2.75 (+0.01)
Biomerica Announces Executive Advisor Appointment for Medical Affairs and Research
Marketwired - Fri Jan 08, 6:11AM CST
Biomerica Inc. (OTCBB: BMRA) announced today the appointment of Charles A. Carter, PharmD, MBA, as a senior advisor with the main responsibilities of Executive Director of Medical Affairs and Research. He will work with the company's Scientific Advisory Board and management to develop and implement strategies to successfully guide products through developmental and regulatory FDA processes.
BMRA: 2.75 (+0.01)
OxySure (OXYS) Launches OxyTrac(TM) to Save Lives & Help Companies Stay Compliant
ACCESSWIRE - Thu Dec 10, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / December 10, 2015 / Suppose that you're at a sporting event and someone in the crowd suffers a heart attack and goes into cardiac arrest. A nearby fan responds quickly and calls for help, but stadium employees aren't quite sure where the nearest AED is located. Once a device is finally located, emergency responders attempt to utilize it, but the battery has died. The person ends up dying at the event and the sporting event is sued for their lack of an appropriate response.
SMED: 4.43 (unch), BMRA: 2.75 (+0.01)
Biomerica Reports First Quarter Results; Sales Up Over 24%
Marketwired - Fri Oct 16, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2015.
BMRA: 2.75 (+0.01)
Biomerica Working With FDA on Submission for Its IBS Product
Marketwired - Tue Sep 29, 6:47AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced today that following a meeting with FDA on September 17, 2015, Biomerica is moving forward with guidance from FDA to develop the optimal clinical and regulatory path to begin clinical studies for its new IBS (Irritable Bowel Syndrome) product. The product is intended to aid in identifying patient specific foods that may exacerbate IBS symptoms. The regulatory path Biomerica is pursuing is a De Novo 510(k) which, if accepted by FDA, would allow Biomerica to attain clearance of its product without filing a PMA (Premarket Approval Application). De Novo approval is generally faster and much less expensive than the PMA route.
BMRA: 2.75 (+0.01)
